Specialist Dr. Gülhan İpek Deniz
PERSONAL INFORMATION
- Date of birth: May 19, 1983
- Foreign language skills: English
EDUCATION INFORMATION
- Faculty of Medicine: Dicle University
- Internal Medicine: Istanbul Training and Research Hospital
- Medical Oncology Subspecialty: Istanbul University Cerrahpaşa Faculty of Medicine
INFORMATION REGARDING WORK EXPERIENCE
- Mardin Nusaybin Health Center No. 2, 2008-2008
- Istanbul Training and Research Hospital 2008-2013
- Gaziosmanpaşa Taksim Training and Research Hospital 2013-2014
- Istanbul University, Cerrahpaşa Faculty of Medicine (2014-2017)
- Muş State Hospital (2017-2017, Istanbul transfer due to spouse's employment)
- Istanbul Şişli Hamidiye Etfal Training and Research Hospital (2017-2020)
- Tansan Private Polyclinic 2020 – …
GENERAL INFORMATION ABOUT CLINICAL RESEARCH
ANNAR 42756493BLC3002
Biomarker Study to Identify Patients with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations
Assistant researcher;
PDR00l
An open-label, multicenter Phase I/II study on the safety and efficacy of PDR00 I administration in patients with advanced malignancies.
MON-7
A Phase III, randomized, double-blind, placebo-controlled study investigating tamoxifen and goserelin, or a nonsteroidal aromatase inhibitor (NSAID) and goserelin in combination with LEE011 or placebo, in the treatment of premenopausal women with Hannon receptor-positive, HER2-negative, advanced breast cancer.
Mon-2
A randomized, double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with advanced, hormone receptor-positive, HER2-negative breast cancer who have not previously received treatment for advanced disease.
MON-3
A randomized, double-blind, placebo-controlled study using ribociclib in combination with fulvestrant in men and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who had not previously received treatment or had only received a series of endocrine therapies.
MCSllO
A randomized, phase II study using carboplatin and gemcitabine in combination with MCS10 in advanced stage triple-negative breast cancer (TNBC).
BOLER0-4
An open-label, single-arm, phase II study in which Everolimus is combined with Letrozol in the treatment of postmenopausal women with estrogen receptor-positive, HER2-negative, metastatic or locally advanced breast cancer.
BOLER0-6
A three-arm, randomized, open-label phase II study comparing everolimus or capecitabine in combination with exemestane in postmenopausal women with estrogen receptor-positive, locally advanced, recurrent, or metastatic breast cancer following recurrence or progression after previous administration of letrozole or anastrozol.
I3Y-MC-JPBM
A placebo-controlled, randomized, double-blind, phase 3 study comparing nonsteroidal aromatase inhibitors (Anastrozole or Letrozole) in combination with a CDK4/6 inhibitor, L Y2835219, or placebo in hormone receptor-positive, HER2-negative, postmenopausal women with locally recurrent or metastatic breast cancer who had not previously received systemic treatment.
I3Y-MC-JPBK JUNIPER
A randomized, phase 3 study comparing abemaciclib and best supportive treatment with erlotinib and best supportive treatment in stage IV non-small cell lung cancer patients with KRAS mutations who experienced progression after platinum-based chemotherapy.
14T-MC-JVDC
A placebo-controlled, randomized, double-blind, phase 3 study comparing ramusirumab with docetaxel and placebo with docetaxel in patients with locally advanced, surgically unresectable, or metastatic urothelial cell carcinoma who experienced progression during or after platinum-based therapy.
14D-MC-JTJH
A Phase 2 study using LY2606368 in patients with advanced-stage small cell lung cancer.
13Y-MC-JPCE
A Phase 2 Study Combining Abemaciclib with Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer.
130-MC-JSBF
A randomized, double-blind, phase 2 study in which cisplatin and gemcitabine are used in combination with ramusirumab, merestinib, or placebo as first-line therapy in patients with advanced or metastatic biliary tract cancer.
I4T-MC-JVCZ
A randomized, phase 2 study evaluating alternative ramusirumab doses in combination with paclitaxel in stage 2 metastatic or locally advanced, unresectable gastric or gastroesophageal junction adenocarcinoma.
lmvigor130
A phase 3, multicenter, randomized, placebo-controlled, double-blind study comparing the combination of atezolizumab (anti-PD-L1 antibody) with gemcitabine/carboplatin to gemcitabine/carboplatin alone in patients with untreated locally advanced or metastatic urothelial carcinoma unsuitable for cisplatin-based chemotherapy.
IMvigor010
- A Phase 1, Open-Label, Multicenter, Randomized Study of Observation vs. Adjuvant Therapy in Patients with PD-L-1 Selective, High-Risk Muscle Invasive Bladder Cancer Following Cystectomy with MPDL3280A (Anti-PD-L-1 Antibody).
aPDL 1 Basket
- An open-label, multi-cohort, phase-1 study of MPDL3280A in advanced solid tumors.
SANDPIPER
- A Phase 11, double-blind, placebo-controlled, randomized study comparing taselisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with estrogen receptor-positive and HER2-negative locally advanced or metastatic breast cancer who experienced disease relapse or progression during or after aromatase inhibitor therapy.
RCC
Sunitinib versus Bevacizumab in combination with MPDL328α (Anti-PD-L1 Antibody) in patients with untreated advanced renal cell carcinoma.
Evaluator
Phase 111 is an open-label, randomized trial.
IMvigor211
A phase 111, open-label, multicenter, randomized trial investigating the efficacy and safety of MPDL3280A (anti-PD-L1 antibody) compared to chemotherapy after failure of platinum-containing chemotherapy in patients with locally advanced or metastatic urothelial bladder cancer. .
JACOB
A double-blind, placebo-controlled, randomized, multicenter Phase 111 study evaluating the efficacy and safety of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-positive metastatic gastroesophageal junction and gastric cancer.
UMBRELLA ML28851
AN OPEN-LABEL, MULTINATIONAL, MULTICENTREPRENEURIAL, PHASE 111 STUDY EVALUATING PATIENT SATISFACTION WITH SUBCUTANEOUS TARSTUZUMAB ADMINISTRATION IN HER2-POSITIVE EARLY-STAGE BREAST CANCER PATIENTS. .
KAMILLA MO28231
A multicenter, single-arm study of trastuzumab emtansine (T-DM1) in patients with locally advanced or metastatic breast cancer who have previously received anti-HER2 and chemotherapy-based treatment and are HER2-positive.
JAVELIN200
“A Phase 111, open-label, multicenter study evaluating avelumab (MSB0010718C) versus docetaxel in patients with non-small cell lung cancer who experienced disease progression after platinum-containing dual therapy.”
impower110
A phase 111, open-label, randomized trial evaluating MPDL3280A (anti-PDL-1 antibody) against cisplatin or carboplatin + pemetrexed in selected, unchemotherapyd stage 4 non-squamous cell non-small cell lung cancer patients for PDL-1.
MK 3475 -061
Phase 111 Randomized Study Comparing Pembrolizumab (MK-3475) with Paclitaxel in Volunteers with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Experiencing Progression After First-Line Therapy with Platinum and Fluoropyrimidine,
Open-label clinical trial.
KEYNOTE-361
Phase 111 Randomized, Controlled Study Evaluating Pembrolizumab Alone or in Combination with Chemotherapy in Advanced Urothelial Carcinoma
MK 3475 -355
A randomized, double-blind, phase 111 study comparing pembrolizumab (MK-3475) plus chemotherapy combination to placebo plus chemotherapy in previously untreated volunteers with inoperable locally advanced or metastatic triple-negative breast cancer.
MDV3100-14
Phase 1 study of Pembrolizumab (MK3475) in volunteers with castration-resistant metastatic prostate cancer (mCRPC) who have previously received chemotherapy.
PROSPER
Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Enzalutamide in Patients with Non-Metastatic Castration-Resistant Prostate Cancer.
Other
Betul Borku Uysal, Feray AUkbas, Esma Altunoglu, Gulhan ipek Deniz, Duygu Uysal, Harun Uysal, Hanife Usta Atmaca, Yasin Yuksel, Hale Aral, Guven Cetin; M. Cem Ar, Mustafa Boz, Fusun Erdenen, The Effect Of Serum Hepcidin Level On Anemia In Heart Failure,
The Korean Journal of Internal Medicine Yol. 29, No. 5 (Suppl. 1), PS 0070, WCIM 2014.
1-Yağbasan Yeşilada Belma, İpek Deniz Gülhan, Ar Muhlis Cem, Çetin Güven, Huq Gül ben, Sametoğlu Fettah (2013). Simple Prognostic Factors in Non-Hodgkin Lymphoma.
39th National Heniatology Congress, (Control No: 679731). .
2-Ahmet Baran, Gülhan İpek Deniz, Sibel Çetin Erdamar, Nuray Kepil, Muharrem Köse, Hande Turna, Çiğdem Papila, Fuat Demirelli (2015).
A Case of Lung Cancer Diagnosed by Colonoscopy. 21st National Cancer Congress (PO 18).
3- Gülhan İpek Deniz, Atakan Demir, Bilge Öz, Sergülen Dervişoğlu, Nil Çomunoğlu, Emire Seyahi Kural, Yıldız Şengül, Hande Turna, Çiğdem Papila, Fuat Demirelli (2015).
Malignant Mesothelioma Cases Developing on the Background of Familial Mediterranean Fever.
21st National Cancer Congress (P062).
4-Gülhan İpek Deniz, Şeımin Güven Meşe, Zerrin Calay, Sinem Koçak, Ahmet Baran, Hande Turna, Çiğdem Papila, Fuat Demirelli (2015). A Rare Case: Primary Neuroendocrine Breast Carcinoma.
21st National Cancer Congress (P223).
5-Sinem Koçak, Gülhan İpek Deniz, Cüyan Demirkesen, Sergülen Dervişoğlu, Hande Turna, Mustafa Özgüroğlu (2015).
Metastatic Kapossi Sarcoma in an Immunosuppressive Background: Two Cases
21st National Cancer Congress (P138).
6- Atakan Demir, Ahmet Baran, Gizem Ayan, Özcan Yıldız, Mesut Yılmaz, Şermin Güven Meşe, Sinem Koçak, Gülhan İpek Deniz, Hande Turna, Mustafa Özgüroğlu, Fuat Hulusi Demirelli
THE EFFECTIVENESS OF SYSTEMIC TREATMENTS IN THYROID CANCERS RESTRUCTURAL TO RADIOACTIVE IODINE THERAPY.
21st National Cancer Congress (P321).
7- Ali Can, Şermin Güven Meşe, Atakan Demir, Gülhan İpek Deniz, Mesut Yılmaz, Ahmet Baran, Sinem Koçak, Z. Hande Turna, Çiğdem Papila, Fuat H. Demirelli. .
NEUROENDOCRINE TUMORS: 10 YEARS OF EXPERIENCE IN A SINGLE CENTER.
21st National Cancer Congress (P370).
8- Şermin Güven Meşe, Ali Can, Atakan Demir, Teoman Yanmaz, Gülhan İpek Deniz, Mesut Yılmaz, Sinem Koçak, Ahmet Baran, Z. Hande Turna, Mustafa Özgüroğlu
Efficacy of Bevacizumab in Recurrent Epithelial Ovarian Cancer.
21st National Cancer Congress (P406).
9- Gülhan İpek Deniz, Sinem Koçak, Şermin Güven Meşe, Mesut Yılmaz, Ahmet Baran, Atakan Demir, Hande Turna, Çiğdem Papila, Fuat Demirelli
Efficacy and Tolerability of Sorafenib in Patients with Hepatocellular Carcinoma
21st National Cancer Congress (P534).
10- Sinem Koçak, Gülhan İpek Deniz, Şermin Güven Meşe, Ahmet Baran, Mesut Yılmaz, Atakan Demir, Hande Turna, Nil Molinas Mandel, Çiğdem Papila, Fuat Demirelli
EFFICACY AND SAFETY OF PAZOPANIB IN SOFT TISSUE SARCOMAS.
21st National Cancer Congress (P408).
11- Gülhan İpek Deniz, Şermin Güven Meşe, Atakan Demir, Mesut Yılmaz, Ahmet Baran, Sinem Koçak, Hande Turna, Fuat Demirelli.(2014)
HOW AGGRESSIVE CAN BASAL CELL CARCINOMA BE?
1st Geriatric Oncology Congress (P005 l).
12-S-004 NATIONAL LUNG CANCER CONGRESS 2020
THE ROLE OF PET/CT IN TARGETED THERAPIES IN LUNG CANCER
Reşit Akyel 1, Emre Demirci 2, Gülhan İpek Deniz 1, 1 Şişli Hamidiye Etfal EAH 2 TC Yeditepe University Koşuyolu Hospital
13-S-009 NATIONAL LUNG CANCER CONGRESS 2020
NON-SMALL CELL LUNG CANCER AND TYROSINE KINASE INHIBITORS
Gülhan İpek Deniz l , 1 Şişli Hamidiye Etfal EAH
14-Abstract P5-11-19: Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access program in Turkey
Umut Demirci, Erhan Gokmen, Yesim Eralp, Seyda Gunduz, Sema Sezgin Goksu, Taner Korkmaz, Osman Kostek, Serdar Turhal, Semra Paydas, Sevgi Topcu, Burcu Cakar, Bulent Karabulut, Ozgur Tanrıverdi, Burcak Karaca, Gulhan Ipek Deniz, Ozkan Alan, Fatma Paksoy Turkoz and Gul Basaran
DOi: 10.1158/1538-7445.SABCS19-P5-11-19 Published February 2020
Book and Magazine Authorship
1- Adjuvant Treatment in Gastric Cancer, CANCER AGENDA Volume: 3/1, March 2015.
Türkiye FIGHT AGAINST CANCER FOUNDATION, Dr. Gülhan İpek Deniz, Istanbul University Cerrahpaşa Faculty of Medicine, Department of Medical Oncology
2. Current Approaches in Surgical and Systemic Treatment of Abdominal Sarcoma
Chapter 11, Systemic Treatment of Desmoid Tumors, Gülhan İPEK DENİZ
3- Approach to Gastrointestinal Stromal Tumors and Neuroendocrine Tumors
Chapter 25, Neuroendocrine Tumor Metastases and Systemic Treatment, Gülhan İPEK DENİZ
Speaker
INNOVATIONS IN NON-MELANOMA SKIN CANCERS Gülhan İpek Deniz Şişli Hamidiye Etfal Training and Research Hospital, Medical Oncology, Istanbul
3rd CONGRESS ON YOUNG PEOPLE'S PERSPECTIVES ON ONCOLOGY 2020